Oncodesign – vector of innovation
Founded nearly 25 years ago by Dr. Philippe Genne, the Company’s CEO and Chairman, Oncodesign is a biopharmaceutical company dedicated to precision medicine. Its main driver is to fill the innovation gap in the healthcare industry with its comprehensive technological platforms integrated in a translational drug discovery engine.
Technological innovation lies at the heart of Oncodesign’s model – the Etiology, Discovery and Experimentation activities designed and implemented by Oncodesign contribute to a more effective approach to the phenomenon of innate and acquired resistance, more efficient treatments and a reduction in therapeutic failures.
Working alongside prestigious big pharma and biotechs (nearly 800 over the last decades), Oncodesign orients with success the R&D of new therapeutic and diagnostic tools.
Throughout our range of services combining state-of-the-art
medicinal chemistry,
pharmacology,
bioanalysis,
DMPK (in GPx environment), imaging and Artificial Intelligence, Oncodesign is the R&D partner for both routine or complex and strategic programs. Our long track record in oncology is also applied to various therapeutic areas inflammation, immunology, immuno-onco and infectious diseases.
Oncodesign’s technology has already enabled the targeting of several promising molecules with substantial therapeutic potential, mainly in oncology.
From France to North America
Oncodesign is based in Dijon, France, in the heart of the town’s university and hospital hub, and within the Paris-Saclay Bio-cluster. Oncodesign has also 2 subsidiaries in Canada and the USA.
Oncodesign has 232 talented employees in France and North America.
We are your partner for both routine or complex projects. Challenge us!
We will be pleased to see you when around!
Explore our large spectrum of offerings and news on Oncodesign.com
For instant news, follow us on
LinkedIn:
https://www.linkedin.com/company/oncodesign
Twitter:
https://twitter.com/Oncodesign_SA
For more information, please contact us.
